The relationship between tumour necrosis factor (TNF)-α promoter andIL12B/IL-23Rgenes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study

Abstract

This study identified a relationship between certain TNF-α and IL12B/IL23R polymorphisms and the short-term response to anti-TNF-α drugs. If these results are confirmed, this information will allow for stratified consent with more accurate prediction of response/personalized choice of treatment hierarchy for the patient.

Pharmacogenetics of Psoriasis Treatment

“…Carriers of the rs11209026 GG genotype showed beter response at 6 months of anti-TNFα treatment compared to non-carriers. This study also showed the association of HLA-Cw6 haplotype with worse outcome [47]. Another association with HLA loci was observed by Masouri et al who reported the association of HLA-C rs10484554 polymorphism with good response to adalimumab (CC or CT genotype, p = 0.007).…”

“…Beter improvement in PASI score after 6 months of treatment with anti-TNFα drugs was achieved in psoriasis patients with TNF -238GG, -857CT/TT and -1031TT genotypes [47]. SNPs in TNF promoter were evaluated also by De Simone et al, and rs361525 (-238G allele; p = 0.03) and rs1800629 (-308GG genotype; p = 0.001) were found to be associated with good drug response [48].…”

Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

“…[33][34][35][36][37][38][39][40][41][42][43] For all significant associations, except TLR9 (rs352139) and LY96 (rs11465996), similar tendencies were observed for ORs for each of the anti-TNF agents (data available on request). To our knowledge, this is one of the largest cohorts for evaluation of response in patients treated with ustekinumab 44,45 and the second largest for evaluation of anti-TNF; only a Canadian study (also involving treatment primarily for psoriatic arthritis) had more patients.…”

Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab

“…It is necessary to investigate also other possible polymorphisms associated with increased production of TNFα or with inadequate response to treatment, such as TNFα polymorphisms at position -238 G/A, -857 C/T, -1031 C/T, -863 C/A , polymorphism of TNFα receptor I (TNFRSF1A), polymorphisms of TNFα receptor II (TNFRSF1B) [5]. Gallo et al [6] showed very good therapeutic response of TNFα blockers in patients with the following polymorphisms: TNF-1031TT (PASI75 at week 12), TNF-238GG, TNF-857CT/TT, TNF-1031TT (PASI75 at week 24). They also showed the importance of IL-23 polymorphism.…”